



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)

Cenderitide

Cat. No.:	HY-P3624	
CAS No.:	507289-11-4	
Molecular Formula:	C ₁₅₈ H ₂₆₃ N ₄₉ O ₅₀ S ₃	Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-
Molecular Weight:	3745.27	Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met-Ser-
Sequence Shortening:	GLSKGCFGLKLDRIKMSGLGCPSLRDRPNAPSTA (Disulfide bridge:Cys6-Cys22)	Gly-Leu-Gly-Cys-Pro-Ser-Leu-Arg-Asp-
Target:	Guanylate Cyclase	Pro-Arg-Pro-Asn-Ala-Pro-Ser-Thr-Ser-
Pathway:	GPCR/G Protein	Ala (Disulfide bridge:Cys ₆ -Cys ₂₂)
Storage:	Sealed storage, away from moisture	
	Powder -80°C 2 years	
	-20°C 1 year	
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)	

SOLVENT & SOLUBILITY

In Vitro

DMSO : 10 mg/mL (2.67 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent	1 mg	5 mg	10 mg
	Concentration	Mass		
1 mM		0.2670 mL	1.3350 mL	2.6700 mL
5 mM		---	---	---
10 mM		---	---	---

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Cenderitide is a potent agonist of particulate guanylyl cyclase receptor (pGC). Cenderitide is a natriuretic peptide (NP) composed of C-type natriuretic peptide (CNP) fused to the C-terminus of Dendroaspis natriuretic peptide (DNP). Cenderitide activates both pGC-A and pGC-B, activates the second messenger cGMP, suppresses aldosterone, and preserves GFR without reducing blood pressure. Cenderitide can be used for heart failure research^{[1][2][3]}.

In Vitro

Cenderitide has antiproliferative, anti-fibrotic, and anti-hypertrophic properties^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

In vivo in normal canines, Cenderitide (10, 50, and 100 ng/kg) is a potent cGMP stimulator that has renal enhancing and cardiac unloading effects, with less reduction of blood pressure^{[1][4]}.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Ichiki T, et al. Natriuretic peptide based therapeutics for heart failure: Cenderitide: A novel first-in-class designer natriuretic peptide. *Int J Cardiol.* 2019 Apr 15;281:166-171.
- [2]. Wojta J. Cenderitide: a multivalent designer-peptide-agonist of particulate guanylyl cyclase receptors with considerable therapeutic potential in cardiorenal disease states. *Eur Heart J Cardiovasc Pharmacother.* 2016 Apr;2(2):106-7.
- [3]. Lisa C Costello-Boerrigter, et al. Cenderitide (CD-NP), a novel peptide designed to activate both guanylyl cyclase B and A, activates the second messenger cGMP, suppresses aldosterone, and preserves GFR without reducing blood pressure in a proof-of-concept study in patients with chronic heart failure. *BMC Pharmacol* 11 (Suppl 1), P18 (2011).
- [4]. Lisy O, et al. Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. *J Am Coll Cardiol.* 2008 Jul 1;52(1):60-8.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA